Project Grant HT94252510884
Award Date 9/15/25
Completion Date 9/14/29
Dollars Obligated $1.6M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
- The MCCAIN/BAYH GLIOBLASTOMA CONSORTIUM federal Project Grant award, funded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), provides $2,564,517.00 to support advanced biomedical research aimed at transforming healthcare for military service members, veterans, and the broader public. The award was granted to Duke University's Office of Research Administration on Sep 15, 2025, with a performance period extending through Sep 14, 2029. The...
- This federal Project Grant award of $1,626,500.00 was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to The Regents of the University of California, San Francisco (UCSF). The grant supports advanced biomedical research aimed at transforming healthcare for military service members, veterans, and the broader public. The research initiative, titled the "MCCAIN/BAYH GLIOBLASTOMA CONSORTIUM," will focus on developing...
- This $1,619,723 federal Project Grant award from the Department of Defense's Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides funding to The University of Texas MD Anderson Cancer Center to conduct research targeting novel mediators of breast cancer brain metastasis. The award period runs from April 1, 2024 to March 31, 2027, with the goal of developing new treatments, improving patient care, and advancing scientific understanding in this...
- The Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $1,619,668 project grant to The University of Texas MD Anderson Cancer Center to inhibit brain metastases of HER2/neu-positive breast cancers using extracellular vesicles from renovated dendritic cells. The award began on May 1, 2024 and is scheduled for completion on April 30, 2027. The project aims to develop innovative treatments to improve outcomes for military service members and the...
- The University of Texas MD Anderson Cancer Center received a $567,000 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant, awarded on September 1, 2024, will fund research targeting myeloid mimicry in renal medullary carcinoma, with a completion date of August 31, 2027. Through this federal grant, MD Anderson Cancer Center will conduct innovative scientific studies, ranging from basic laboratory research to advanced...
- This federal Project Grant award of $1,348,314.00 was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to The University of Texas MD Anderson Cancer Center. The funding supports a research project titled "BUILDING T-CELL PRODUCTS IN NF1-ASSOCIATED MPNST THROUGH ANTIGEN DISCOVERY AND EPIGENOME TARGETING". The project aims to conduct advanced biomedical research to transform healthcare for military service members,...
- The U.S. Defense Health Agency has awarded a $7,001,734 Project Grant to The University of Texas MD Anderson Cancer Center to advance the understanding of metastatic breast cancer through the development of a comprehensive research platform. The grant, which runs from August 15, 2024 to August 14, 2028, is funded under the Military Medical Research and Development (CFDA 12.420) program. The project aims to drive innovative cancer research and explore new approaches to prevention, diagnosis,...
- This $1,882,607 Project Grant award, funded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research at the University of Texas MD Anderson Cancer Center to leverage prostate cancer's unique lipid metabolism to induce therapeutic ferroptosis. The 3-year research project, which commenced on March 15, 2025, aims to develop innovative approaches for treating prostate cancer by exploiting the disease's metabolic vulnerabilities. As a...
- This $3,945,543 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports cancer research and care initiatives at the University of Texas MD Anderson Cancer Center (MD Anderson). The award will fund a 4-year clinical research extension project to advance progress, precision, and equity in breast cancer care. MD Anderson, a leading comprehensive cancer center, will utilize the funding to conduct research activities that...
- The University of Texas MD Anderson Cancer Center received a $647,998 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The award will fund research to develop image-guided, bidirectional EphB4 agonist-based therapy for ovarian cancer over a 4-year period from September 1, 2023 to August 31, 2027. MD Anderson, a comprehensive cancer treatment and research center, has extensive experience conducting basic,...